PTC Therapeutics Inc (PTCT)

Drugs • Health Care

Stock AI

News & Reports

July 16, 2026 PTC Therapeutics Set to Release Second Quarter 2026 Financial Results PTC Therapeutics will report its Q2 2026 financial results on July 30, 2026, via a live webcast. Investors can access the event online or by phone, with a replay available for 30 days.

June 17, 2026 PTC Therapeutics Announces New Employee Inducement Grants PTC Therapeutics has approved significant inducement grants, including stock options and RSUs, for 18 new hires to attract talent. This initiative highlights PTC's strategy to build a skilled workforce for advancing rare disorder treatments.

June 16, 2026 PTC Therapeutics Announces $500 Million Convertible Notes Offering PTC Therapeutics has announced a $500 million offering of convertible senior notes to refinance existing debt and support growth. The proceeds will primarily repurchase existing notes and fund corporate purposes. This strategic financial move is set to enhance the company's market position and shareholder value.

June 15, 2026 PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes PTC Therapeutics is proposing a $500 million offering of Convertible Senior Notes due in 2031 to refinance its existing 2026 notes. The funds will be used for debt repurchase and general corporate purposes. This strategic move reflects PTC's commitment to enhancing its financial position.

May 04, 2026 PTC Therapeutics Inc. to Showcase Innovations at Investor Conferences PTC Therapeutics is set to present at major healthcare conferences in May and June, emphasizing its commitment to transparency and innovation in rare disorder treatments. Live streaming of presentations will be available, with archived access for continued insights into the company's strategic initiatives.

April 28, 2026 PTC Therapeutics Reports Positive Interim Results from PIVOT-HD Extension Study of Votoplam PTC Therapeutics announced positive interim results from its PIVOT-HD extension study, showing votoplam significantly slows progression of Stage 2 Huntington's disease. The findings support the ongoing Phase 3 INVEST-HD study, which aims to further evaluate votoplam's effectiveness.

April 28, 2026 PTC Therapeutics Reports Promising Results from PIVOT-HD Long Term Extension Study PTC Therapeutics announced significant findings from the PIVOT-HD study, evaluating votoplam for Huntington's disease. The results support ongoing collaborations and future FDA actions, highlighting votoplam's innovative mechanism to reduce toxic HTT protein levels.

April 22, 2026 PTC Therapeutics Set to Announce First Quarter 2026 Financial Results PTC Therapeutics is set to announce its financial results for Q1 2026 in a webcast on May 7. The call will provide insights into their innovative pipeline and strategic goals aimed at addressing rare disorders.

April 17, 2026 PTC Therapeutics Approves Inducement Grants for New Employee PTC Therapeutics has approved inducement grants for a new non-executive employee, including stock options and RSUs, to enhance talent acquisition. This move aligns with PTC's mission to develop innovative solutions for rare disorders.

March 25, 2026 PTC Therapeutics Strengthens Board with Appointment of Jessica Chutter PTC Therapeutics has appointed Jessica Chutter to its Board of Directors, enhancing its leadership as it pursues growth in the biotech sector. With over 40 years of experience in biotech investment banking, Chutter's insights are expected to play a crucial role in the company's strategic evolution.

February 23, 2026 PTC Therapeutics Set to Engage Investors at Upcoming Conferences PTC Therapeutics, Inc. will participate in several investor conferences in March 2026, presenting updates on its innovative pipeline and corporate strategies. The events provide a platform for the company to connect with investors and showcase its advancements in the biopharmaceutical sector.

February 19, 2026 PTC Therapeutics Reports Strong Year-End Results and Corporate Update PTC Therapeutics reported robust financial results for 2025, driven by the successful launch of Sephience, achieving $831 million in revenue. The company anticipates further growth and expansion in 2026, highlighting its strong market position and innovative R&D programs.

February 19, 2026 PTC Therapeutics Inc. 2025 Annual Report: Navigating Growth Amidst Challenges PTC Therapeutics' 2025 Annual Report details significant advancements, including the successful launch of Sephience and financial growth despite challenges with other products. The report also highlights strategic partnerships and a promising recovery trajectory.

February 12, 2026 PTC Therapeutics Inc. Withdraws NDA Resubmission for Translarna™: A Critical Regulatory Update PTC Therapeutics has announced the withdrawal of its NDA resubmission for Translarna™ following FDA concerns about efficacy data. This setback emphasizes the challenges faced by biopharmaceutical companies in demonstrating drug effectiveness for rare disorders like Duchenne muscular dystrophy.

February 05, 2026 PTC Therapeutics Inc. to Report Fourth Quarter and Full Year 2025 Financial Results PTC Therapeutics will host a conference call on February 19, 2026, to discuss its financial results for Q4 and the full year of 2025. The call aims to provide insights into the company's performance and future strategies, reinforcing its commitment to transparency and stakeholder engagement.

January 12, 2026 PTC Therapeutics Inc. Updates Investors at J.P. Morgan Healthcare Conference PTC Therapeutics presented a positive update at the J.P. Morgan Conference, highlighting a successful 2025 with strong revenues and strategic goals for 2026, including new product launches and R&D advancements. The company aims to maintain growth and improve patient outcomes through innovative therapies.

January 08, 2026 PTC Therapeutics Inc. Announces Inducement Grants for New Employee PTC Therapeutics has approved 300 restricted stock units (RSUs) for a new employee, emphasizing its commitment to attracting top talent in the biopharmaceutical sector. This strategic inducement grant aligns employee interests with the company's mission to develop innovative therapies for rare disorders.

December 22, 2025 PTC Therapeutics Secures Approval for Sephience™ in Japan: A Game-Changer for PKU Patients PTC Therapeutics has received approval for Sephience™ in Japan, providing a new treatment option for phenylketonuria (PKU) patients. The launch is anticipated after pricing discussions conclude in early 2026, signaling hope for those affected by this metabolic disorder.

December 19, 2025 PTC Therapeutics Expands Workforce with Inducement Grants PTC Therapeutics recently approved inducement grants to attract five new employees, providing stock options and RSUs as part of their compensation. This strategic move aims to enhance the company's talent pool and strengthen its position in the biopharmaceutical industry.

December 18, 2025 PTC Therapeutics to Showcase Innovations at J.P. Morgan Healthcare Conference PTC Therapeutics will showcase its innovations at the J.P. Morgan Healthcare Conference on January 12, 2026. With a focus on rare disorders, the company aims to highlight its transformative medicines and future strategies, reinforcing its commitment to patient accessibility and scientific advancement.

December 01, 2025 PTC Therapeutics Expands Workforce with Inducement Grants PTC Therapeutics has announced stock option and RSU grants for 15 new employees to strengthen its workforce. This strategic move underscores the company's commitment to addressing rare disorders and advancing its pipeline of innovative medicines.

November 20, 2025 PTC Therapeutics Announces Upcoming R&D Day to Highlight Pipeline Advancements PTC Therapeutics is set to host an R&D Day on December 2, 2025, to update stakeholders on its pipeline and research initiatives. The event will feature insights from CEO Dr. Matthew B. Klein and the R&D team, focusing on new targets in rare disorder treatments.

November 04, 2025 PTC Therapeutics Reports Strong Third Quarter 2025 Results Amid Sephience Launch PTC Therapeutics reported strong financial results for Q3 2025, with total revenues of $211 million, driven by the successful launch of Sephience. The company achieved a net income of $15.9 million, reflecting improved cost management and growth in its product portfolio.

November 04, 2025 PTC Therapeutics Inc. Reports Q3 2025 Financial Results: A Mixed Bag of Progress and Challenges PTC Therapeutics reported mixed Q3 2025 results with $131M in revenue, highlighting new product launches like Sephience while facing regulatory challenges. The company shows improved net income but navigates significant liabilities and market risks ahead.

October 31, 2025 PTC Therapeutics to Showcase Innovations at Upcoming Investor Conferences PTC Therapeutics will present at several key healthcare investor conferences, sharing insights on their innovative treatments for rare disorders. These events are vital for investor engagement and highlight the company's commitment to addressing unmet medical needs.

October 27, 2025 PTC Therapeutics Induces New Talent with Stock Options and RSUs PTC Therapeutics has approved inducement grants for new employees, featuring stock options and RSUs to attract top talent. This initiative aligns with their commitment to innovation in rare disorder treatments.

October 21, 2025 PTC Therapeutics to Share Third Quarter 2025 Financial Results in Upcoming Conference Call PTC Therapeutics will host a webcast conference call on November 4, 2025, to discuss its Q3 financial results and business updates. Participants can register online for access and a replay will be available afterward.

October 01, 2025 PTC Therapeutics Announces Inducement Grants for New Hires PTC Therapeutics has approved inducement grants for 48 new hires, including stock options and RSUs, as part of its strategy to attract top talent in the biopharmaceutical sector. This move aligns with Nasdaq regulations and emphasizes the company's growth ambitions.

August 21, 2025 PTC Therapeutics to Showcase Innovations at Upcoming Investor Conferences PTC Therapeutics will showcase its advancements at three major investor conferences in September 2025, highlighting its commitment to rare disease treatments. Investors can access live webcasts to gain insights into the company’s innovative pipeline and strategies.

August 19, 2025 PTC Therapeutics Faces Setback as FDA Issues Complete Response Letter for Vatiquinone PTC Therapeutics has encountered a significant setback as the FDA issued a Complete Response Letter for vatiquinone, a treatment for Friedreich's ataxia. The FDA's concerns center on the lack of substantial efficacy evidence, prompting the need for further studies. PTC remains committed to addressing these issues and advancing its innovative therapies.

August 07, 2025 PTC Therapeutics Inc. Reports Strong Q2 2025 Financial Results and Corporate Update PTC Therapeutics reported strong Q2 2025 results, with $179 million in revenue, driven by the launch of Sephience for PKU and solid DMD product sales. Despite a net loss, the company maintains a robust financial position and anticipates significant revenue growth for the year.

August 07, 2025 PTC Therapeutics Inc. Reports Mixed Results in Q2 2025 PTC Therapeutics reported mixed results in Q2 2025, with a significant FDA approval for Sephience but a decline in net product revenue. Despite challenges, the company shows strong liquidity and potential for future growth in the biopharmaceutical sector.

July 28, 2025 PTC Therapeutics Secures FDA Approval for Sephience™: A New Era for PKU Treatment PTC Therapeutics has received FDA approval for Sephience™, a groundbreaking treatment for Phenylketonuria (PKU), applicable for patients as young as one month. Supported by robust clinical evidence, this therapy addresses significant unmet needs in PKU management, promising improved quality of life.

July 21, 2025 PTC Therapeutics to Discuss Q2 2025 Financial Results in Upcoming Conference Call PTC Therapeutics will hold a conference call on August 7, 2025, to discuss its Q2 financial results, focusing on its drug development efforts and market strategies. Stakeholders are encouraged to register in advance for this informative session.

June 23, 2025 PTC Therapeutics Announces European Approval for Sephience™ in PKU Treatment PTC Therapeutics has received European Commission approval for Sephience™ (sepiapterin), a treatment for phenylketonuria (PKU) applicable across all ages and severities. The approval is backed by promising clinical trial results and sets the stage for a launch in Germany in July 2025.

June 19, 2025 PTC Therapeutics Expands Workforce with Inducement Grants PTC Therapeutics has announced inducement grants to attract 34 new employees, including stock options and RSUs. This strategic move aims to strengthen its workforce and enhance its mission to develop innovative therapies for rare disorders.

May 06, 2025 PTC Therapeutics Inc. Reports Q1 2025 Results: Navigating Challenges with Mixed Financial Performance PTC Therapeutics Inc. reported a net income of $866.5 million for Q1 2025, a turnaround from a loss in the previous year, driven by collaboration revenues. Despite challenges with key products and regulatory hurdles, the company remains focused on innovation and growth in rare disease treatments.

May 06, 2025 PTC Therapeutics Reports Strong First Quarter 2025 Results and Corporate Update PTC Therapeutics posted a robust first quarter of 2025 with $190 million in revenue, primarily from its DMD treatments. The company also highlighted significant clinical advancements and revised its full-year revenue guidance upwards, showcasing a strong financial outlook.

May 05, 2025 PTC Therapeutics Announces Positive Results from PIVOT-HD Study for Huntington's Disease Treatment PTC Therapeutics has shared promising results from its PIVOT-HD study, demonstrating a significant reduction in Huntingtin protein levels in Huntington's disease patients. The treatment, PTC518, shows potential for long-term neuroprotective effects and a favorable safety profile, paving the way for future regulatory discussions on accelerated approval.

May 01, 2025 PTC Therapeutics Inc. Announces Inducement Grants for New Employees PTC Therapeutics has awarded inducement grants to 12 new hires, consisting of stock options and restricted stock units. This initiative aims to attract top talent and bolster innovation in the biopharmaceutical sector, reinforcing the company's commitment to developing treatments for rare disorders.

April 25, 2025 PTC Therapeutics Receives Positive CHMP Opinion for Sephience™ in PKU Treatment PTC Therapeutics has received a positive opinion from the CHMP for Sephience™, an innovative treatment for phenylketonuria (PKU). This approval addresses unmet medical needs across all ages and severity levels, with plans for a European launch following regulatory approval. Sephience™ offers a dual mechanism of action, enhancing enzyme function and potentially allowing dietary liberalization.

April 24, 2025 PTC Therapeutics Inc. Announces Participation in Upcoming Investor Conferences PTC Therapeutics, Inc. will participate in several investor conferences in May and June 2025, showcasing its innovative pipeline for rare disorders. The events will provide insights into the company's strategies and growth potential in the biopharmaceutical sector.

April 17, 2025 PTC Therapeutics Set to Reveal First Quarter 2025 Financial Results PTC Therapeutics will host a conference call on May 6, 2025, to discuss its Q1 2025 financial results. This call will provide valuable insights into the company's performance and commitment to innovative therapies for rare disorders.

March 28, 2025 PTC Therapeutics Inc. Announces Inducement Grants for New Employees PTC Therapeutics has approved stock options and RSUs for 35 new employees to attract skilled talent, aligning their interests with the company's growth in rare disorders. These competitive compensation packages reflect PTC's commitment to enhancing its workforce and addressing patient needs.

March 28, 2025 PTC Therapeutics Faces Regulatory Setback in Europe for Translarna™ PTC Therapeutics faces a regulatory setback as the European Commission declines to renew Translarna™'s marketing authorization for nmDMD. Despite this, individual EU countries may still access the treatment, highlighting ongoing challenges for patients with this condition.

March 20, 2025 PTC Therapeutics Unveils Promising Sepiapterin Data at ACMG Meeting PTC Therapeutics presented promising data on sepiapterin at the ACMG meeting, showing over 97% of PKU patients improved their dietary tolerance. This treatment could enhance quality of life for those with the disorder.

February 27, 2025 PTC Therapeutics Inc. Reports Mixed Financial Results for 2024 PTC Therapeutics Inc. reported mixed financial results for 2024, with a 14% decline in revenue primarily due to reduced product sales. Despite operational losses, the company remains optimistic, focusing on innovative treatments and recent FDA designations.

February 27, 2025 PTC Therapeutics Inc. Reports Strong Financial Performance and Strategic Advancements in 2024 PTC Therapeutics reported a total revenue of $213 million for Q4 2024, down from 2023, but showed significant improvement in net loss. The company made strides in regulatory approvals and formed key partnerships, positioning itself for growth in 2025.

February 20, 2025 PTC Therapeutics Announces Key Participation in Upcoming Investor Conferences PTC Therapeutics will participate in two major investor conferences in March 2025, highlighting their innovative pipeline and commitment to rare disease therapies. Both events will be accessible via live webcast.

February 19, 2025 SWOT Analysis of PTC Therapeutics Inc in 2025 This article provides a detailed SWOT analysis of PTC Therapeutics Inc as of 2025, examining its strengths like innovative therapies and weaknesses such as revenue reliance. It also discusses opportunities in emerging markets and threats from intense competition and regulatory changes.

February 19, 2025 PTC Therapeutics Secures FDA Acceptance and Priority Review for Vatiquinone NDA PTC Therapeutics has announced FDA acceptance of its NDA for vatiquinone, aimed at treating Friedreich's ataxia. The drug shows promise backed by clinical trials and has been given Priority Review status, suggesting it may be the first approved therapy for this condition.

February 13, 2025 PTC Therapeutics Set to Unveil Q4 and Full Year 2024 Financial Results PTC Therapeutics will hold a conference call on February 27, 2025, to discuss its Q4 and full year 2024 financial results. The call will provide insights into the company's performance and future strategies, crucial for investors and stakeholders.

November 07, 2024 PTC Therapeutics Inc. Reports Q3 2024 Financial Results: A Year of Transition and Growth PTC Therapeutics Inc. reported a net revenue of $196.7 million for Q3 2024, showing slight growth but a reduced net loss of $106.6 million. The company continues to advance its innovative pipeline while facing challenges such as increased liabilities and market access issues.

August 08, 2024 PTC Therapeutics Inc. Reports Q2 2024 Financial Results: A Mixed Bag Amidst Strategic Refocus PTC Therapeutics Inc. faced a challenging second quarter in 2024 with a 24% drop in net product revenues, though it improved its net loss significantly. Strategic cost management efforts and a 44% rise in royalty revenues from Evrysdi offer glimpses of potential recovery amidst ongoing financial hurdles.

April 25, 2024 PTC Therapeutics Inc. Reports Q1 2024 Financial Results: A Mixed Bag of Performance and Challenges PTC Therapeutics Inc. reported mixed financial results for Q1 2024, with total revenues of $210.1 million and a net loss of $91.6 million. Despite a decline in Translarna sales, the company's focus on R&D and a strong product pipeline, including Upstaza, positions it for future growth.

PTC Therapeutics Set to Engage Investors at Upcoming Conferences

Last updated: February 23, 2026 •

Taurigo

PTC Therapeutics, Inc. (NASDAQ: PTCT) has announced its participation in a series of prominent investor conferences taking place in March 2026. This initiative is part of the company's ongoing commitment to engage with the investment community and provide updates on its innovative pipeline and corporate strategies.

1. Conference Schedule

PTC Therapeutics will feature its executive team at the following events:

TD Cowen 46th Annual Health Care Conference

Date: Monday, March 2, 2026

Time: 9:50 a.m. ET

Leerink 2026 Global Healthcare Conference

Date: Tuesday, March 10, 2026

Time: 4:20 p.m. ET

Barclays Global Healthcare Conference

Date: Wednesday, March 11, 2026

Time: 8:00 a.m. ET

These conferences represent a key opportunity for PTC to showcase its advancements in the biopharmaceutical sector and to discuss its strategic vision with investors and analysts.

2. Live Webcast and Accessibility

The presentations will be available for live streaming on the Events and Presentations page located in the Investor section of PTC Therapeutics' website. Interested stakeholders are encouraged to connect to the website several minutes before the start of each presentation to ensure a smooth connection. Additionally, the webcasts will be archived for a period of 30 days following each event, allowing for flexible viewing options.

3. About PTC Therapeutics, Inc.

PTC Therapeutics is a global biopharmaceutical entity focused on the discovery, development, and commercialization of clinically differentiated medicines aimed at treating rare disorders. The company's mission centers on providing access to high-quality treatments for patients with unmet medical needs. PTC Therapeutics is committed to advancing a robust and diversified pipeline of transformative medicines, leveraging its scientific expertise and global commercial infrastructure to optimize value for patients and stakeholders alike.

For more insights and updates, PTC encourages interested parties to visit their website and follow them on social media platforms including LinkedIn, X (formerly Twitter), Instagram, and Facebook.

4. Conclusion

As PTC Therapeutics prepares for these crucial investor conferences, it continues to reinforce its position as a leader in the biopharmaceutical industry. With a focus on rare disorders and a commitment to innovative solutions, the company is poised to attract attention from investors looking for opportunities in this dynamic sector.

Original press release

You may also be interested in: